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absence of pathogens. Such sterile inﬂammation is dependent
on a cytosolic complex of proteins inside immune cells termed
the inﬂammasome. This complex converts two groups of extra-
cellular signals into an inﬂammatory response via activation of
caspase-1 and secretion of IL-1b and IL-18. Group 1 signals are
typically TOLL like receptor agonists and result in transcriptional
upregulation of inﬂammasome components and pro-cytokines.
Group 2 signals are diverse, ranging from uric acid to ATP, and
lead to assembly and activation of the inﬂammasome complex.
Inﬂammasome components are required for a wide range of
acute and chronic pathologies, including experimental alcoholic
and non-alcoholic steatohepatitis, and drug-induced liver injury.
Collectively, group 1 and 2 signals, inﬂammasome components,
and cytokine receptors provide a rich source of therapeutic tar-
gets. Many of the advances in the ﬁeld have come from standard
reductionist experiments. Progress in the understanding of com-
plex human systems will, however, be dependent on novel strat-
egies such as systems analysis, which analyze large data sets to
provide new insights.
Published by Elsevier B.V. on behalf of the European Association
for the Study of the Liver.
Introduction
The development of inﬂammation after tissue injury has been
known since ancient times, and occurs in the absence of patho-
gens. Such sterile inﬂammation (SI) is pervasive in a wide range
of pathologies, and is signiﬁcant because it can increase the over-
all organ damage after the primary insult. Alcoholic and non-
alcoholic steatohepatitis (ASH and NASH), and drug induced liver
injury (DILI) have SI as an important component of liver damage.
Such a generic recognition of a role for SI, and characterization of
some of the cellular and cytokine components was comple-Journal of Hepatology 20
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Open access under CC BY-NC-ND license.was the theoretical proposal that cell death results in the release
and production of molecules which are not present in the extra-
cellular environment during health (damage associated molecu-
lar patterns – DAMPs). The second was the identiﬁcation of a
range of DAMPs which possess a wide range of structures from
true pattern molecules such a nuclear and mitochondrial DNA,
to small molecules like ATP and large crystals like uric acid. The
third was identiﬁcation of the cell surface receptors and
mechanisms activated by DAMPs, and the fourth was identiﬁca-
tion of the cytosolic machinery in innate immune cells which is
activated by DAMP signals and has been termed the inﬂamma-
some. These discoveries overlapped with much of what was
known about immune activation by pathogens, by pathogen
associated molecular patterns (PAMPs), including the fact that
many of the PAMP receptors such as TLRs are also activated by
DAMPs.
Key Points
• Cell death results in inflammation even in the absence
of pathogens (sterile inflammation)
• Sterile inflammation can increase organ damage
• The inflammasome is a cytosolic protein complex that
is required for the development of sterile inflammation
• Many liver diseases such as alcoholic steatohepatitis,
non-alcoholic steatohepatitis, and drug-induced liver
injury have sterile inflammation as a major component
• The above pathways have allowed for the development
of novel therapies and the repositioning of older 
therapies
The current understanding of activation of inﬂammasome
pathways in SI is shown in Fig. 1. Two broad types of signals
are required in most cells for full activation of this pathway
and production of the inﬂammatory cytokines IL-1b and IL-18.
Signal 1 is delivered by a number of TLR ligands (Table 1) and
results in transcriptional upregulation of pro-IL-1b pro-IL-18
and inﬂammasome components. A number of cytokine receptors
share the signaling domain MyD88 used by most TLRs and can13 vol. 58 j 1047–1052
ROS + Ca++
Cathepsin B
ASC
NALP Pro-caspase-1
TLRs
IL-1
TNF-α
P2X7   
receptor
K+ efflux
ATP
Pro-IL-1β
Pro-IL-18
Nucleus IL-1β
IL-18
IL-1β
IL-18Crystals
Caspase-1
Phagolysosome
Phagosome
Signal 1 Signal 2
Cellular membrane
Fig. 1. Mechanisms of inﬂammasome activation. Two types of signals are required for inﬂammasome activation and production of mature IL-1b and IL-18. Signal-1: This
results in the production of pro-IL-1b and pro-IL-18 through interaction of various DAMPs/PAMPs and cytokines like TNF-a with TLRs and TNFR. Signal-2: This leads to
inﬂammasome activation through multiple signaling pathways. MSU and other crystals result in the formation of phagolysosomes. Another pathway of inﬂammasome
activation is via activation of the P2X7 receptor. The activation of inﬂammasome results in the cleavage and activation of the proteases caspase-1 which subsequently
cleaves pro-IL-1b and pro-IL-18 to mature IL-1b and IL-18 that are secreted out of the cell. ASC, apoptosis-associated speck-like protein containing a CARD; ATP, adenosine
triphosphate; DAMPs, disease associated molecular patterns; IL-1b, interleukin-1beta; IL-18, interleukin-18; MSU, monosodium urate; PAMPs, pathogen associated
molecular patterns; ROS, reactive oxygen species; TLRs, toll like receptors; TNF-a, tumor necrosis factor-alpha; TNFR, tumor necrosis factor receptor.
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loop. Signal two can be provided by a highly diverse range of
molecules (Table 1) and result in assembly of the inﬂammasome
machinery, which includes cytosolic proteins ASC (apoptosis-
associated speck-like protein containing a CARD), NALP (NACHT,
LRR, and PYD-containing protein) and caspase-1. Mitochondria
likely form a central component proximal to inﬂammasome acti-
vation and integrate these diverse signals. The key step in inﬂam-
masome activation is cleavage and activation of caspase-1 which
can subsequently cleave and activate the pro-cytokines pro-IL-1b
and pro-IL-18. Both these cytokines are relatively proximal in the
inﬂammatory cascade and result in the production of TNF-a and
IFN-c which can induce liver injury by a variety of mechanism.The inﬂammasome and liver disease
The typical ﬁrst line of investigation is to test experimental mod-
els of liver disease in mice genetically deﬁcient (knockout, KO) in1048 Journal of Hepatology 2013individual inﬂammasome components. This has been done for
several, but not all, inﬂammasome components in experimental
models of ASH, NASH, ischemia reperfusion (IR) and DILI. Such
approaches have limitations but there is a broad consensus that
many steps of the inﬂammasome pathways shown in Fig. 1 are
necessary for the development of experimental ASH, NASH, IR
and DILI (Table 1).
TLR4 and 9 are the ones most reported, and this may simply
be because they are the most investigated.Cell speciﬁc roles of inﬂammasome components
The functional roles of inﬂammasome components were initially
identiﬁed in innate immune cells particularly macrophages and
explain their rapid production of inﬂammatory mediators in
response to pathogen and damage associated molecular patterns.
In the liver, this suggests a major role for inﬂammasome path-
ways in Kupffer cells (KC), and this has been conﬁrmed in avol. 58 j 1047–1052
Table 1. Molecules required for sterile inﬂammatory diseases of the liver.
Signal 1 Signal 2 Downstream pathways
Alcoholic steatohepatitis TLR4 [1] ASC, caspase-1, IL1-R [2]
Non-alcoholic steatohepatitis TLR4 and 9 [1,3] IL-1R [3]
Ischemia reperfusion TLR4 and 9 [4,5]
Drug induced liver injury TLR4 and 9 [6,7] P2x7 [8], MSU [9] ASC, caspase-1, IL-1R
Fibrosis TLR4 and 9 [10,11] IL1-R [3]
Table 2. Inhibitors of signal 1 and 2 and downstream steps.
Agent Inhibition of Safety data
Signal 1
Eritoran [14] TLR4 (selective) Yes
Glycyrrhizin [16,17] HMGB1 Yes
Ethyl pyruvate [23] TLR4 Yes
Melatonin [25] TLR4 Yes
Curcumin [28] TLR4 Yes
Anti-HMGB1 Ab HMGB1 No
IRS954 TLR7 and 9 No
Signal 2
GS-9450 [36] Caspase 1 Yes
A438079 P2X7 No
Febuxostat [37] Xanthine oxidase Yes
Allopurinol [38] Xanthine oxidase Yes
Downstream signals
Anakinra [39] IL-1R Yes
Fostamatinib [40] Syk Yes
JOURNAL OF HEPATOLOGYmodel of NASH where high levels of IL-1b production were
observed in the KC fraction, and in vivo depletion of KC resulted
in a signiﬁcant decrease in IL-1b levels [3]. Supporting data for
a major role for macrophages comes from the fact that baseline
levels of inﬂammasome components were 20-fold higher in
mononuclear cells than hepatocytes, and LPS only induced an
increase in the mononuclear fraction [2]. This was further con-
ﬁrmed by depleting KC in vivo in models of alcoholic steatohep-
atitis, which resulted in a reduction in liver injury comparable
to the total caspase-1 deﬁcient animals. The signals from injured
hepatocytes, which induce inﬂammasome activation in KC, are
likely to include a number of the approximately 20 known
DAMPs.
Detailed expression analysis of inﬂammasome components
reveals prominent expression in KC and liver sinusoidal endothe-
lial cells, moderate levels in periportal myoﬁbroblasts and hepa-
tic stellate cells, and virtually none in primary cultured
hepatocytes [12]. Interestingly, challenge with LPS resulted in a
time- and concentration-dependent expression of a number of
inﬂammasome molecules in cultured hepatic stellate cells and
hepatocytes. This makes it possible that at certain stages of dis-
ease states, inﬂammasome activation in parenchymal cells can
have important biological roles, but this has not been fully
explored.Inhibition of signal 1
Due to the early identiﬁcation of TLR4, it was an early target of
antagonist development. The antagonist eritoran reduced acute
liver injury and inﬂammation in a rat model of DILI mediated
by galactosamine [13]. Eritoran has also been investigated in a
large randomized clinical trial as therapy for sepsis, intravenous
eritoran demonstrated a trend toward lower mortality in subjects
with severe sepsis and high APACHE II scores (Table 2) [14]. Func-
tional antagonists of TLR4 signaling include inhibitors of HMGB1,
the purported major endogenous ligand in acute and chronic liver
injury. These include glycyrrhizin, an inhibitor of HMGB1 expres-
sion, which has been shown to decrease inﬂammation in murine
models of acute acetaminophen (APAP) injury and ischemia
reperfusion injury [15]. Clinical validation of the efﬁcacy of intra-
venous glycyrrhizin in liver injury has been explored in a ran-
domized controlled trial of chronic HCV, where it was
administered chronically and shown to signiﬁcantly reduce
serum ALT, but not HCV RNA levels [16]. More recently, intrave-
nous glycyrrhizin has been shown to promote transaminase nor-
malization in patients with acute autoimmune hepatitis though
this prospective study did not have a steroid alone comparator
arm to compare to the standard of care therapy [17]. Anti-
HMGB1 blocking antibodies have been shown to protect fromJournal of Hepatology 2013acetaminophen and concanvalin-induced acute liver injury, but
have not been tested in humans [18,19].
Ethyl pyruvate supplementation has been shown to suppress
TLR4 mediated pro-inﬂammatory responses and liver injury and
inﬂammation in murine models of ischemia reperfusion injury,
extrahepatic cholestasis, and alcohol-induced acute liver injury
[20–22]. The mechanism of this therapeutic beneﬁt remains
poorly deﬁned. The only published clinical trial of ethyl pyruvate
showed no therapeutic beneﬁt in patients undergoing cardiopul-
monary bypass [23]. Melatonin suppresses TLR4-mediated
inﬂammation and is hepatoprotective in a murine LPS and galac-
tosamine toxin model of liver injury [23,24]. In a human clinical
trial in NASH patients, oral melatonin administered for 12 weeks
signiﬁcantly reduced serum AST and GGT in patients at 12-week
follow-up relative to placebo [25].
Curcumin suppresses LPS mediated release of HMBG1 and
presumably ampliﬁcation of TLR4 mediated immune responses
[26]. Curcumin protects the liver against injury and ﬁbrogenesis
caused by carbon tetrachloride in rats in part through suppres-
sion of inﬂammation [27]. Anti-inﬂammatory efﬁcacy of oral cur-
cumin has not been examined in human liver injury but has been
recently investigated in the peri-operative period of coronary
artery bypass graft, where it showed a signiﬁcant reduction in
in-hospital myocardial infarction as well as post-operative C-
reactive protein levels [28]. TLR-7/9 antagonists, speciﬁcally the
synthetic oligonucleotide IRS 954, has demonstrated great efﬁ-
cacy as a therapy in a murine model of acetaminophen-inducedvol. 58 j 1047–1052 1049
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acute liver injury, reducing liver necrosis, hemorrhage, and
inﬂammation [7].Inhibition of signal 2
There are numerous small molecule antagonists of purinergic
receptor P2X7mediatedpro-inﬂammatory signaling. Additionally,
there are agents known to enzymatically deplete the P2X7 ligand
ATP, speciﬁcally apyrase, as well as small molecular competitive
inhibitors of the P2X7 ligand NAD, speciﬁcally etheno-NAD. The
P2X7 small molecule antagonist A438079, apyrase, and etheno-
NAD all demonstrate efﬁcacy inmitigating liver injury and inﬂam-
mation in a murine model of acetaminophen-induced acute liver
injury [8]. Additionally, P2X7 receptor expression on lymphocytes
is required for liver injury and inﬂammation in a murine model of
autoimmune hepatitis induced by concanavalin A [29].
Uric acid crystals, similar to all other particulates, activate the
Nlrp3 inﬂammasome. Pharmacologic antagonism of uric acid
crystal deposition targets the enzyme xanthine oxidase, required
for purine catabolism to uric acid. Allopurinol is an isomer of
hypoxanthine that competitively inhibits purine catabolism
through xanthine oxidase and has demonstrated clinical efﬁcacy
in lowering serum uric acid levels and decreasing the frequency
of disease ﬂares in gout. Allopurinol was dose-dependently pro-
tective of hepatocellular injury in a murine model of APAP-
induced acute liver injury and warm ischemia reperfusion injury
in rabbits [30]. Of note, allopurinol has antioxidant effects which
may mediate hepatoprotection independent of alterations in uric
acid metabolism. Febuxostat is an orally administered non-pur-
ine selective small molecule inhibitor of xanthine oxidase with
demonstrated clinical efﬁcacy in lowering serum uric acid. There
are no published studies investigating the efﬁcacy of febuxostat
in liver injury, but febuxostat decreases kidney injury in a rat
model of renal warm ischemia reperfusion injury [31]. This posi-
tive ﬁnding may be related to a reduction in oxidative stress
mediated by metabolites generated by xanthine oxidase, though
a role for the Nlrp3 inﬂammasome in mediating ischemia reper-
fusion injury has been recently deﬁned [32].
Selective pharmacologic antagonism of caspase-1 has not been
extensively investigated in experimental models of acute liver
injury. The pan-caspase inhibitor IDN-6556 attenuated hepatic
injury and ﬁbrosis in a murine model of cholestatic liver injury
mediated by bile duct ligation [33]. A double-blind placebo con-
trolled trial of oral IDN-656 demonstrated efﬁcacy in lowering
serum aminotransferase levels in patients with chronic hepatitis
C after two weeks of administration [34]. The selective caspase 1
inhibitor YVAD-CMK was found to be hepatoprotective in several
murinemodels of immuneand toxin-mediated liver injury, includ-
ing LPS/galactosamine and Fas ligand injury [35]. More recently, a
phase 2, randomized clinical trial investigating the oral caspase-
1,8,9 inhibitor GS-9450 administration over 4 weeks, in patients
with biopsy proven NASH, demonstrated signiﬁcant reductions
in serum aminotransferase [36].Other inhibitors of inﬂammasome pathways
The recombinant human interleukin-1 receptor antagonist ana-
kinra is hepatoprotective in rodent models of acute liver injury,
including warm ischemia reperfusion injury and acetamino-1050 Journal of Hepatology 2013phen-induced acute liver injury [2]. To date, anakinra has not
been investigated as therapy in clinical liver disease.
Syk tyrosine kinase is required for Nlrp3 inﬂammasome sens-
ing of fungal and malarial antigens [41]. Recently, syk tyrosine
kinase was identiﬁed as required for Nlrp3 inﬂammasome activa-
tion by foreign bodies [42]. The implications of this biology to ster-
ile inﬂammation in the liver are yet to be determinedbutmayhave
a role in hepatic ﬁbrogenic responses to foreign materials such as
talc or encysted parasites. To date, syk inhibitors have not been
investigated in clinical or experimental liver disease. The oral syk
inhibitor R788 (fostamatinib) did not demonstrate clinical efﬁcacy
with regard to primary end points in the treatment of rheumatoid
arthritis in a randomized clinical trial [40].Systems biology to model experimental data to predict clinical
outcomes
Inﬂammasome-regulating and -driven processes can drive either
self-sustaining inﬂammation or, alternatively, promote pathways
that ultimately lead to ﬁbrosis. These processes are dynamic,
multi-dimensional, and multi-scale in nature. A reductionist, sin-
gle-pathway study of the inﬂammasome would beneﬁt from syn-
thesis via systems approaches, including data-driven and
mechanistic computational modeling. These approaches have
been employed alone and in concert in order to study the acute
inﬂammatory response in cells, in experimental animals and in
humans, and have resulted in translational applications such as
in silico clinical trials and individual-speciﬁc models [43–45].
Though to date there have not been explicit computational
models of the inﬂammasome, the role of IL-1 in inﬂammation
has been modeled computationally [44,45]. Initial, unpublished
in vitro studies from our group suggest that TLR-mediated inﬂam-
matory networks in macrophages drive a chemokine-mediated
switching architecture that ultimately leads to inﬂammasome
activation. A key hypothesis, derived from these and related stud-
ies, is that inﬂammation may be regulated via direct or indirect
positive feedback loops that control switching behavior between
beneﬁcial and detrimental inﬂammatory responses.
Insights such as these may drive a future generation of inﬂam-
masome-targeted, personalized therapies. Such therapies are
likely to be targeted at one or more of the aforementioned targets
(e.g., TLR4, TLR7, TLR9, or the IL-1 receptor). The key to such ther-
apies will be speciﬁcity to the receptor, the speciﬁc downstream
signaling cascade(s), and the inﬂammatory mediators that are
modulated by such therapies. Proceeding frommodels of TLR4 sig-
naling of various degrees of complexity and model-derived
insights on the ultimate roles of IL-1 in inﬂammation as applied
to individual subjects, such computational models, would need
to integrate the ever-increasing data on inﬂammasome biology
[44–49].Wewould envision a likely need formodulating different
aspects of the intersecting TLR-NLR pathways with ﬁne speciﬁcity,
in a disease- (and possibly individual-) speciﬁc fashion. To do so,
computational simulations could be employed both to design clin-
ical trials and to predict the responses of individuals [43].Conclusions
The data from KO animals suggests a role for inﬂammasome
pathways in a number of liver disease models. Data from a broadvol. 58 j 1047–1052
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range of diseases outside the liver suggests that this is a robust
conclusion. In addition, data from release of DAMPs and success
with antagonist strategies provides further support. DAMPs have
also been detected in comparable human diseases and tissues. As
with all newly discovered pathways, a strategy of customized
small molecule inhibitors can be pursued. There is, however, fur-
ther excitement in this ﬁeld because agents such as TLR antago-
nists have already undergone clinical trials for sepsis and
autoimmunity, and this has generated safety data. Other drugs
are actually in clinical use, and include uricosuric agents such
as febuxostat, and the IL-1R antagonist anakinra, which is cur-
rently in use to treat patients with rheumatoid arthritis. Novel
approaches such as systems biology promise to allow a synthesis
of the experimental data to provide a rational approach to select-
ing the best candidates to clinical trials in ASH, NASH, DILI and
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